Table 1 Clinical characteristics and results of thyroid autoantibodies stratified by interval period over 35 years
From: Practice patterns and outcomes in the management of Thai patients with Graves’ disease
Total (N = 2736) | 1985–1994 (N = 144) | 1995–2004 (N = 416) | 2005–2014 (N = 1209) | 2015–2019 (N = 967) | |
|---|---|---|---|---|---|
Female (%) | 82.0% | 87.5% | 85.6% | 80.3% | 81.7% |
Age at diagnosis | 36.3 + 12.0 | 33.0 + 9.7 | 34.7 + 10.9 | 36.0 + 12.4 | 37.8 + 12.1 |
- Age < 40 years | 80.5% | 72.2% | 70.2% | 66.9% | 62.0% |
- Age 40–59 years | 35.8% | 27.8% | 28.6% | 27.5% | 32.3% |
- Age ≥ 60 years | 5.7% | – | 1.2% | 5.6% | 5.7% |
Family history of thyroid disorders (%) | 41.2% | 30.6% | 38.0% | 44.3% | 40.1% |
Smoking status (%) | |||||
-Non-smoker | 96.4% | 97.9% | 98.0% | 96.7% | 95.1% |
-Ex-smoker | 0.9% | – | 1.0% | 0.7% | 1.3% |
-Active smoker | 2.7% | 2.1% | 1.0% | 2.6% | 3.5% |
Weight status at initial presentation | |||||
-Weight loss | 85.0% | 81.2% | 83.9% | 84.4% | 86.8% |
-Weight neutral | 11.6% | 13.2% | 13.0% | 12.6% | 9.5% |
-Weight gain | 3.4% | 5.6% | 3.1% | 3.0% | 3.7% |
Estimated thyroid size | |||||
-Small | 43.0% | 25.0% | 41.8% | 46.4% | 41.9% |
-Medium | 41.5% | 54.9% | 42.6% | 38.6% | 42.6% |
-Huge | 15.5% | 20.1% | 15.6% | 15.0% | 15.5% |
Graves’ Ophthalmopathy(%) | |||||
-No GO | 83.9% | 77.8% | 79.3% | 87.8% | 81.9% |
-Mild GO | 13.3% | 21.5% | 19.2% | 9.6% | 14.1% |
-Moderate to Severe GO | 2.8% | 0.7% | 1.5% | 2.6% | 4.0% |
Pretibial myxedema | 0.1% | – | – | 0.1% | 0.2% |
Thyrotoxic periodic paralysis (%) | 2.3% | – | 3.1% | 1.8% | 2.8% |
Coexisting thyroid disease | |||||
- Solitary thyroid nodule | 2.2% | 3.5% | 1.7% | 2.3% | 2.1% |
`- Multinodular goiter | 3.4% | 2.1% | 1.4% | 3.4% | 4.3% |
- Thyroid cancer | 0.2% | – | 0.2% | 0.2% | 0.3% |
Positive Anti-TPO (%)a | 71.9% | 73.8% | 77.6% | 75.8% | 65.6% |
Positive Anti-Tg (%)b | 61.3% | 31.7% | 53.6% | 71.7% | 52.4% |